Man Group
VRTX icon

Man Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Man Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,200
Closed -$218K – 2124
2021
Q3 		$218K Buy
+1,200
New +$234K ﹤0.01% 1742

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Man Group's VRTX Position: Q1 2026 in Review

Man Group reduced its Vertex Pharmaceuticals (VRTX) stake by 38% in Q1 2026, selling an estimated $67.1M and leaving 236,798 shares worth $106M. The position accounts for 0.19% of the portfolio, ranked #122.

Man Group first reported a position in VRTX in Q1 2018 and has held it in 30 quarters since. The position peaked at $221M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Man Group held 236,798 shares of Vertex Pharmaceuticals worth $106M as of Q1 2026.
  • Man Group sold 143,937 Vertex Pharmaceuticals shares in Q1 2026, an estimated $67.1M.
  • Vertex Pharmaceuticals made up 0.19% of Man Group's portfolio in Q1 2026, its #122 holding.
  • Man Group first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
  • Man Group's Vertex Pharmaceuticals position peaked at $221M in Q1 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.